11:52 AM EST - Helix BioPharma Corp. : announced the recent submission of a Clinical Trial Application with Health Canada for approval to initiate a Phase I clinical trial with L-DOS47. The study is entitled "A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine in Patients with Metastatic or Advanced Solid Tumours. Helix BioPharma Corp.
shares T.HBP are trading down $0.10 at $1.90.
